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OBJECTIVE—To examine the role of aldo-keto reductases
(AKRs) in the cardiovascular metabolism of the precursors of
advanced glycation end products (AGEs).
RESEARCH DESIGN AND METHODS—Steady-state kinetic
parameters of AKRs with AGE precursors were determined using
recombinant proteins expressed in bacteria. Metabolism of meth-
ylglyoxal and AGE accumulation were studied in human umbil-
ical vein endothelial cells (HUVECs) and C57 wild-type, akr1b3
(aldose reductase)-null, cardiospeciﬁc-akr1b4 (rat aldose reduc-
tase), and akr1b8 (FR-1)-transgenic mice. AGE accumulation and
atherosclerotic lesions were studied 12 weeks after streptozoto-
cin treatment of C57, akr1b3-null, and apoE- and akr1b3-apoE–
null mice.
RESULTS—Higher levels of AGEs were generated in the cytosol
than at the external surface of HUVECs cultured in high glucose,
indicating that intracellular metabolism may be an important
regulator of AGE accumulation and toxicity. In vitro, AKR 1A and
1B catalyzed the reduction of AGE precursors, whereas AKR1C,
AKR6, and AKR7 were relatively ineffective. Highest catalytic
efﬁciency was observed with AKR1B1. Acetol formation in
methylglyoxal-treated HUVECs was prevented by the aldose
reductase inhibitor sorbinil. Acetol was generated in hearts
perfused with methylglyoxal, and its formation was increased in
akr1b4-o rakr1b8-transgenic mice. Reduction of AGE precur-
sors was diminished in hearts from akr1b3-null mice. Diabetic
akr1b3-null mice accumulated more AGEs in the plasma and the
heart than wild-type mice, and deletion of akr1b3 increased AGE
accumulation and atherosclerotic lesion formation in apoE-null
mice.
CONCLUSIONS—Aldose reductase–catalyzed reduction is an
important pathway in the endothelial and cardiac metabolism of
AGE precursors, and it prevents AGE accumulation and athero-
sclerotic lesion formation. Diabetes 58:2486–2497, 2009
N
onenzymatic glycation and oxidation of pro-
teins and lipids results in the formation of
advanced glycation end products (AGEs) (1,2).
The AGEs are formed when -dicarbonyl and
oxoaldehydes react with amines (Maillard reaction).
These reactions generate multiple products that lead to
Amadori modiﬁed proteins or aminophospholipids.
AGEs are generated normally as tissues age, but they
are formed at an accelerated rate during diabetes (3,4).
Excessive AGE formation has been linked to cross-
linking of matrix molecules such as collagen, vitronec-
tin, and laminin (3,5,6). In addition binding of AGEs to
receptor of AGE (RAGE) results in the activation of
mitogen-activated protein (MAP) kinases, nuclear factor
(NF)-B, and cAMP response element binding (CREB)
(7,8). These events stimulate the production of reactive
oxygen species and lead ultimately to an increase in
vascular permeability and inﬂammation. The pathologi-
cal signiﬁcance of such receptor-mediated events is
underscored by studies showing that RAGE blockage
suppresses accelerated atherosclerotic lesion formation
in diabetic mice (9), decreases neointimal expansion
(10), and restores diabetic deﬁcits in wound healing
(11). Pharmacological blockage or genetic deletion of
RAGE has been shown also to decrease albuminuria and
mesangial expansion/glomerulosclerosis in mouse mod-
els of type 1 diabetes (12). Taken together, these studies
suggest that the AGEs are signiﬁcant mediators of
hyperglycemic injury.
In most tissues, AGEs are derived from products
generated from the auto-oxidation of glucose and fruc-
tose. These include deoxyglucosone, methylglyoxal, and
glyoxal (1,2). Methylglyoxal is generated nonenzymati-
cally from the oxidation and spontaneous dismutation
of intermediates in the glycolysis pathway or enzymatic
oxidation reaction catalyzed by peroxidases, whereas
other AGE precursors such as deoxyglucosone are
generated from fructose or from nonenzymatic degrada-
tion of Amadori rearrangement compounds (13). Previ-
ous studies show that the AGE precursor methylglyoxal
is metabolized and detoxiﬁed by the glyoxalase system
consisting of glyoxalase-I and -II (14,15). Nevertheless,
the participation of other enzymes in the metabolism of
methylglyoxal and other AGE precursors remains
unclear. In vitro studies show that members of the
aldo-keto reductase (AKR) superfamily catalyze methyl-
glyoxal reduction (16,17), and in bacteria these enzymes
participate in the conversion of methylglyoxal to acetol
(18,19). Nevertheless, the in vivo role of AKRs in
mammalian metabolism of AGE precursors has not been
studied. Accordingly, we tested the efﬁcacy of several
AKRs in catalyzing the reduction of AGE precursors.
Our results show that reduction catalyzed by aldose
reductase (AKR1B) is a signiﬁcant metabolic fate of
AGE precursors in endothelial cells and in the heart and
that this metabolism prevents AGE accumulation during
diabetes and atherosclerosis.
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RESULTS
High glucose–induced AGE formation. AGEs are gen-
erated from nonenzymatic processes both in the cytosol
and at the external matrix. To examine AGE abundance in
these compartments, human umbilical vein endothelial
cells (HUVECs) were cultured in media containing normal
(5.5 mmol/l) and high (30 mmol/l) glucose for 7 days, and
AGE formation was measured. Western analysis of the
total cell lysates using the anti-argpyrimidine antibody
showed that cells cultured in high glucose accumulated
more AGEs than those grown in normal medium (Fig. 1A).
Upon two-dimensional gel electrophoresis and matrix-
assisted laser description ionization–mass spectrometry
(MALDI-MS) analysis, the major immunopositive protein
was identiﬁed to be HSP27 (Fig. 1A, inset), indicating that
intracellular proteins are most likely to participate in AGE
formation. These observations are in agreement with the
studies by Schalkwijk et al. (20), showing that high glucose
selectively increases argpyrimidine adduct formation
(with HSP27) in endothelial cells. However, to examine
the extent of formation of extracellular AGEs, intact cells
were stained with the anti-argpyrimidine antibody and cell
ﬂuorescence was measured by ﬂuorescence-activated cell
sorter. To measure intracellular AGEs, the cells were
permeabilized and then treated with anti-argpyrimidine
antibody. Although minimal ﬂuorescence was detected in
nonpermeabilized cells (Fig. 1B[i, ii]), permeabilization
increased ﬂuorescence in both normal and high glucose–
treated cells (Fig. 1B[iii, iv]). Relative ﬂuorescence was
higher in cells cultured in high glucose than in normal
glucose medium. These data indicate that high glucose
promotes AGE formation and that most AGEs are gener-
ated in intracellular proteins such as HSP27. It follows
then that accumulation and toxicity of AGEs is likely to be
regulated not only by processes that generate AGE form-
ing species but also by intracellular pathways that metab-
olize AGE precursors.
Relative efﬁcacy of AKRs in AGE reduction. Although
methylglyoxal and glyoxal are known to be metabolized by
glyoxalases (14,15), the metabolism of other AGE precur-
sors remains unknown. It is also unclear whether methyl-
glyoxal and glyoxal are metabolized by pathways other
than glyoxalases. Hence, we measured the catalytic efﬁ-
ciencies of the human AKRs (AKR1, AKR6, and AKR7
families), some of which have been shown to catalyze
methylglyoxal reduction in vitro (16). For these experi-
ments, the AKR coding sequences containing His-tag were
expressed in Escherichia coli and the proteins were
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FIG. 1. High glucose–induced AGE formation. A: Western blot analysis of total cell lysates prepared from HUVECs cultured in the presence of
normal (NG; 5.5 mmol/l) or high (HG; 30 mmol/l) glucose for 7 days and probed with anti-argpyrimidine antibodies. Western blots from two
representative experiments are shown. Inset shows the major immunopositive spot resolved by two-dimensional gel analysis of the cell lysates.
The spot, corresponding to a molecular weight of 27 kDa and a pI of 7.83, was identiﬁed to be HSP27 by MALDI/MS analysis. B:
Fluorescence-activated cell sorter data obtained from HUVECs cultured in normal (i, iii) and high (ii, iv) glucose. Extracellular AGEs were
detected by labeling the cells with the anti-argpyrimidine antibody and phycoerythrin-conjugated secondary antibody. To detect total
(extracellular  intracellular) AGEs, the cells were permeabilized before antibody treatment. Relative mean ﬂuorescence was calculated by
subtracting the ﬂuorescence obtained from the isotype-matched antibody control. Group data are presented as means  SE. *P < 0.05 vs. normal
glucose; n  3–4.
S.P. BABA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2487puriﬁed on a Ni-afﬁnity column. Using glyoxal or methyl-
glyoxal as substrates, highest catalytic efﬁciency was
observed with AKR1B1 (human aldose reductase). For
both AKR1B1 and AKR1B3 (mouse aldose reductase),
methylglyoxal was a better substrate than glyoxal. AKR1A4
(aldehyde reductase) was also an efﬁcient catalyst for
methylglyoxal reduction, although its catalytic activity
with glyoxal was much less than that of AKR1B1.
Members of the AKR1C and AKR7A5 family displayed
low catalytic efﬁciencies, mostly because of their high
Km values (Table 1).
AKR1B1 was also efﬁcient at catalyzing the reduction of
furfural and hydroxymethylfurfural, which are the major
AGE precursors found in food (21). Daily human con-
sumption of hydroxymethylfurfural is about 50 mg/kg per
day (22). Furfural was reduced by AKR1B1, AKR1B3, and
AKR1B10 with a catalytic efﬁciency that was higher than
glyoxal. In contrast, hydroxymethylfurfural was poorly
reduced by any of the AKRs. AKR1B1 and AKR1B3 were
also efﬁcient with the AGE precursor 3-deoxyglucosone,
which was reduced efﬁciently by AKR1A4 as well (Table 1).
Collectively, these data indicate that AKR1B1 (aldose
reductase) is the most efﬁcient enzyme involved in the
reduction of several naturally occurring AGE precursors.
The role of other AKRs, however, could not be discounted.
Some of these enzymes displayed high kcat values with the
AGE precursors, and their contribution to AGE metabo-
lism may depend upon their relative abundance in speciﬁc
tissues and the presence of other pathways of subsidiary
metabolism.
Reductive metabolism of AGE precursors. Given that
our results indicated that AKRs catalyze the reduction of
AGE precursors and that AGEs accumulate intracellularly,
we tested whether in cells methylglyoxal undergoes reduc-
tive transformation. For this, HUVECs were incubated
with methylglyoxal, and their lysates were used to mea-
sure acetol formation. Upon gas-liquid chromatography
analysis, reagent methylglyoxal (Rt  13.1; Fig. 2A[i]) was
TABLE 1
Steady-state kinetic parameters for the reduction of AGE precursors by AKRs
Substrates
Genbank
accession
number Proteins Km (M) kcat (min
1)
kcat/Km
(min
1/M
1)
Glyoxal NM_021473 AKR1A4 3,229  904 45.8  4.2 0.014
NM_001628 AKR1B1 350  20 29.5  2.02 0.082
NM_009658 AKR1B3 333  62 12.1  0.36 0.036
NM_009731 AKR1B7 7,450  1,500 5.6  0.35 0.001
NM_008012 AKR1B8 635  81 20  0.52 0.031
NM_020299 AKR1B10 7,800  359 8.87  0.63 0.002
NM_030611 AKR1C3 NDA — —
NM_013778 AKR1C6 12,073  1,031 12.8  0.67 0.001
NM_134066 AKR1C18 NDA — —
NM_025337 AKR7A5 5,931  1,393 12.87  0.27 0.002
Methylglyoxal AKR1A4 874  91 483  0.27 0.55
AKR1B1 22  2 37.2  2.21 1.698
AKR1B3 35  4 19.5  2.3 0.56
AKR1B7 1,996  274 8.9  0.31 0.004
AKR1B8 184  15 18.2  1.21 0.098
AKR1B10 1,250  89 26.82  5 0.389
AKR1C3 NDA — —
AKR1C6 139  35 7.65  0.7 0.054
AKR1C18 NDA — —
AKR7A5 9,075  1,250 22  0.7 0.002
Furfural AKR1A4 5,918  1,379 17.4  0.78 0.002
AKR1B1 316  34 30.86  1.91 0.097
AKR1B3 69  10 13.36  0.93 1.91
AKR1B7 NDA — —
AKR1B8 622  100 2.6  0.27 0.001
AKR1B10 1,617  287 178  15 0.11
AKR1C3 156  35 3.09  0.33 0.019
Hydroxymethyl Furfural AKR1A4 6,428  1,479 24.05  4 0.003
AKR1B1 482  92 14.55  2 0.03
AKR1B3 98  15 4.15  0.3 0.042
AKR1B7 NDA — —
AKR1B8 1,197  117 7.82  0.05 0.016
AKR1B10 1,117  135 100  15 0.085
AKR1C3 1,939  425 167  0.02 0.008
Deoxyglucosone AKR1A4 2,067  178 777  25 0.376
AKR1B1 112  5 38.9  2 0.345
AKR1B3 89  5 11.6  1 0.13
AKR1B10 3,293  118 14.36  1.9 0.004
AKR1B10 3,293  118 14.36  1.9 0.004
Enzyme activity was measured in 0.1 mol/l potassium phosphate (pH 7.0) using the indicated substrates and 0.15 mmol/l NADPH at room
temperature. Proteins were reduced with dithiothreitol before assay. NDA, no detectable activity.
AKR AND METABOLISM OF AGE PRECURSORS
2488 DIABETES, VOL. 58, NOVEMBER 2009 diabetes.diabetesjournals.orgwell separated from acetol (Rt  7.5; Fig. 2A [ii]). Mass
analysis of acetol revealed characteristic fragments with
m/z 326 and 285 (Fig. 2A[ii]). Similar fragments were
obtained with
13C3-acetol (m/z 329 and 286) with expected
shift in mass. Using the
13C3-labeled internal standard, the
abundance of acetol was measured from cells that were
either left untreated or treated with the AKR1B inhibitors
sorbinil or tolrestat. Ions with m/z 285 and 326 were used
to quantify the abundance of natural acetol. The concen-
tration of these ions was calculated using m/z 286 and 329
ions of the
13C-internal standard. In cells incubated with
methylglyoxal, the average concentration of acetol was
6.2  0.7 (n  4) nmoles/mg protein. Treatment with
sorbinil or tolrestat led to a signiﬁcant decrease in the
intensity of these ions (Fig. 2A[iii]). These results demon-
strate that in HUVECs, AKR1B catalyzes the reduction of
methylglyoxal to acetol.
To examine the role of AKR1B in regulating AGE
formation, HUVECs were cultured in high glucose (30
mmol/l) media and steady-state levels of the most abun-
m/z
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FIG. 2. Methylglyoxal metabolism in endothelial cells. A: GC-MS analysis of acetol formation in HUVECs. For acetol quantiﬁcation,
13C3-methylglyoxal was synthesized from
13C3-acetone and
13C3-acetol was prepared by incubating
13C3-methylglyoxal with AKR1B1 and 0.15
mmol/l NADPH. i: Natural and
13C3-methylglyoxal were derivatized using O-(2,3,4,5,6 pentaﬂourobenzyl)-hydroxylamine hydrochloride (PFBHA)
extracted in hexane and separated by gas chromatography. The 1,2 dioxime methylglyoxal eluted with a retention time of 13.1 min (inset). On
MS analysis, the fragmentation pattern of
12C-1,2, dioxime methylglyoxal showed a parent ion with m/z 462. Ions with m/z 432 and 265
represented the loss of nitric oxide (NO) [M-30] and OC7H3F5 [M-197] groups, respectively, from 1,2 dioxime methylglyoxal. Corresponding ions
with m/z 465, 435, and 268 are because of the
13C3-methylglyoxal. ii: Acetol was derivatized using PFBHA and N,O-bis (trimethylsilyl)
triﬂuoroacetamide with trimethylchlorosilane (BSTFA). Derivatized acetol eluted with a retention time of 7.5 min (inset). Ions with m/z 326 and
285 were assigned to TMS-2-oxime acetol suffering a loss of CH3 [M-15] or C3H4O [M-56], respectively. Corresponding ions with m/z 329 and 286
are because of
13C3-acetol. iii: Acetol formation in HUVECs, cultured in media containing 1 mmol/l methylglyoxal for 24 h in the absence and
presence of the AKR1B inhibitors sorbinil (50 mol/l) or tolrestat (25 mol/l). After treatment,
13C3-acetol was added to cell lysates and lysates
were derivatized and analyzed by GC-MS. *P < 0.05 vs. control. B: Western analysis of lysates prepared from HUVECs cultured in normal (NG)
or high (HG) glucose, with or without sorbinil (50 mol/l), probed with anti-argpyrimidine and anti-HSP27 antibodies. Intensity of immunopo-
sitive band (argpyrimidine) was normalized to HSP27. Data are presented as means  SE. *P < 0.05 vs. normal glucose (n  4) and #P < 0.05
vs. high glucose without sorbinil (n  4).
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As before, incubation with glucose increased the levels of
antiarpyrimidine reactive HSP27, but the abundance of
AGE-HSP27 was increased further in cells treated with
sorbinil. No changes in the total protein levels of HSP27
were observed. In addition to the anti-argpyrimidine anti-
body, which recognizes arginine adducts of methylglyoxal,
we also examined the formation of adducts between
glyoxal and lysine using the anti-carboxymethyl lysine
(CML) antibody. Treatment with high glucose, however,
did not increase anti-CML reactivity, and this reactivity
was not affected by sorbinil (data not shown), indicating
that under the experimental conditions studied, arginine
adducts were more abundant. Overall, these results indi-
cated that in HUVECs inhibition of AKR1B (aldose reduc-
tase) increases the formation and accumulation of
argpyrimidine containing HSP27.
Role of AKR1B in methylglyoxal metabolism. To de-
termine whether methylglyoxal is metabolized to acetol in
the heart, wild-type and AKR1B4 (rat aldose reductase)
transgenic mouse hearts were continuously perfused with
methylglyoxal, and the perfusate was collected. The ex-
pression of the transgene was driven by the -myosin
heavy chain promoter, leading to cardiomyocyte-restricted
increase in gene expression; thus changes in methyl-
glyoxal metabolism could be attributed to cardiomyocyte-
speciﬁc metabolism. Gas chromotography–mass spec-
trometry (GC-MS) analysis of the perfusate revealed
clearly resolved ions with m/z 285 and 326, which were
ascribed to acetol. The concentration of acetol in efﬂuents
of aldose reductase–transgenic hearts was signiﬁcantly
higher (45  4 pmoles/ml) than that collected from wild-
type hearts (25  3 pmoles/ml; Fig. 3A), indicating that an
increase in aldose reductase in the heart increases the
metabolism of methylglyoxal to acetol.
Myocytes isolated from mouse hearts expressed
AKR1B3 (aldose reductase), AKR1B8 (FR-1), but not
AKR1A3 (Fig. 3B). To establish the contribution of these
enzymes, reduction of methylglyoxal was measured in
cardiac homogenates of wild-type, AKR1B4-transgenic,
and AKR1B8-transgenic hearts, with cardiomyocyte-re-
stricted expression of the transgene. Signiﬁcant rates of
methylglyoxal reduction were observed in wild-type car-
diac homogenates. Methylglyoxal reduction was inhibited
by sorbinil, indicating that the reaction was catalyzed by
AKR1B (Fig. 3C). That AKR1B reduces methylglyoxal in
the heart is further supported by data showing a signiﬁcant
increase in reduction rates in hearts of AKR1B4 or
AKR1B8-transgenic mice (Fig. 3C). In agreement with in
vitro data (Table 1), the methylglyoxal reductase activity
in AKR1B4-transgenic mice was 35% higher than methylg-
lyoxal reductase activity in the AKR1B8-transgenic hearts,
indicating that AKR1B1/3/4 is a better methylglyoxal re-
ductase than AKR1B8. Based on these observations, we
conclude that aldose reductase (AKR1B1/3/4) plays a
major role in the reductive metabolism of methylglyoxal;
however, AKR1B8 can also catalyze methylglyoxal
reduction.
Because the puriﬁed AKR1B proteins were found to
catalyze the reduction of several different AGE precursors,
we also measured the reduction of major AGE precursors
in cardiac homogenates of wild-type and AKR1B3-null
mice. Methylglyoxal and deoxyglucosone reductase activ-
ities (Fig. 4A[ii, iii]) in wild-type mice were similar in
magnitude to the DL-glyceraldehyde reductase activity in
these hearts (Fig. 4A[i]), whereas, glyoxal reduction (Fig.
4A[iv]) was twofold lower than the DL-glyceraldehyde
reductase activity. Reduction of AGE precursors was
signiﬁcantly inhibited by sorbinil in wild type but not in
AKR1B3-null, consistent with the involvement of AKR1B3
in this reduction.
In addition to AKRs, glyoxalase I is also involved in the
metabolism of methylglyoxal. To determine the relative
contribution of the two enzymes to the overall methyl-
glyoxal metabolism, we measured the expression and
activity of glyoxalase I in cardiac homogenates of wild-
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FIG. 3. AKR-catalyzed reduction of methylglyoxal in mouse heart. A:
Acetol generated in efﬂuents of isolated wild-type (C57) or aldose
reductase–transgenic hearts perfused with 20 mol/l methylglyoxal.
Acetol concentration was measured by GC-MS after derivatization
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mice probed with antibodies raised against AKR1B1 (aldose reduc-
tase), AKR1B8 (FR-1), and AKR1A4 (ALDR). Figure shows bands from
three different mice. C: Rate of methylglyoxal reduction in homoge-
nates prepared from hearts of wild-type mice (n  6) or mice with
cardiac myocyte–speciﬁc transgene expressing AKR1B4 (rat aldose
reductase; n  6) or AKR1B8 (FR-1; n  6). The enzyme activity was
determined with 1 mmol/l methylglyoxal and 0.15 mmol/l NADPH, with
or without 1 mol/l sorbinil. Inset shows Western blots from wild-type
and transgenic hearts developed with anti–aldose reductase and anti–
FR-1 antibodies. *P < 0.01 vs. wild type (control), #P < 0.01 vs. aldose
reductase–transgenic (control), and §P < 0.01 vs. FR1–transgenic
(control). AR-TG, aldose reductase–transgenic; WT, wild type.
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abundant in the heart, and its abundance was not affected
by deletion of the akr1b3 gene. Our kinetic measurements
indicated that 100  8 nmoles  min
1  mg
1 protein of
S-D-lactoylglutathione (a product of glyoxalase I) were
generated in the heart. S-D-lactoylglutathione formation
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bromobenzylglutathione cyclopentyl diester (BBGC) (Fig.
4B[i]), indicating that it is primarily derived from glyox-
alase I. Approximately, 3–4 nmoles  min
1  mg
1 protein
of S-glycolylglutathione were formed by glyoxalase I when
glyoxal was used as substrate (Fig. 4B[ii]). The values of
the kinetic parameter of glyoxalase I were similar to those
reported by Allen et al. (23). No glyoxalase I activity was
observed with deoxyglucosone. Metabolism of methyl-
glyoxal by glyoxalase I was 10-fold higher than the
methylglyoxal reductase activity by AKR1B3: 10  2
nmoles acetol  min
1  mg
1 protein; (Fig. 4A[i]). Forma-
tion of S-glycolylglutathione by glyoxalase I from glyoxal
was, however, approximately the same as the reduction of
glyoxal by AKR1B3 (Fig. 4A[iv]). To assess the relative
contribution of aldose reductase and glyoxalase I in the
metabolism of AGE precursors in the heart, we performed
simulation experiments using the steady-state kinetic pa-
rameters listed in supplemental Table 1. These calcula-
tions suggest that at low concentrations (glyoxal 1–100
mol/l and methylglyoxal 1–20 mol/l) aldose reductase–
catalyzed reduction accounts for 85% of glyoxal and
40% of methylglyoxal metabolism, whereas glyoxalase I
contributes to 15% glyoxal and 60% methylglyoxal
metabolism. At higher concentrations, the relative contri-
bution of glyoxalase I increases as a function of substrate
concentration. This analysis is in agreement with the
kinetic model of methylglyoxal metabolism in yeast (24).
Together, these analyses suggest that both aldose reduc-
tase and glyoxalase I play signiﬁcant and nonredundant
roles in the metabolism of AGE precursors.
Regulation of AGE formation by AKR1B3. To examine
how AKR1B3 regulates AGE formation in diabetes, wild-
type and akr1b3-null mice were made diabetic by injecting
streptozotocin (STZ). Control mice were treated with the
vehicle alone. Induction of diabetes led to an increase in
A1C levels from 5.4  1.1% to 7.9  1.1% after 8 weeks of
diabetes. The STZ-injected mice showed marked hypergly-
cemia, and the levels of plasma glucose, when measured
after 12 weeks, were slightly higher in the aldose reducta-
se–null than wild-type mice (supplemental Table 2). De-
tectable levels of multiple argpyrimidine-derived AGEs
were present in murine plasma. Quantiﬁcation of clearly
resolved band at 27 kDa showed that the intensity of this
band was higher in diabetic mice (Fig. 5A). The intensity of
this band was even greater in akr1b3-null diabetic mice,
indicating that deletion of this gene increases the forma-
tion of 27 kDa argpyrimidine AGE in the plasma of diabetic
mice. Similar changes were observed when AGE forma-
tion was detected using the anti-CML antibody. As shown
in Fig. 5B, increased accumulation of CML AGEs (2- to
12-fold) p27, p40, and p100 kDa was detected in the plasma
of diabetic and nondiabetic akr1b3-null mice. Overall, the
akr1b3-null diabetic plasma showed a greater plasma AGE
accumulation than plasma from wild-type mice. These
data suggest that deletion of the akr1b3 gene increases
AGE accumulation in the plasma.
To evaluate changes in tissue levels, AGE formation was
quantiﬁed in the heart. In hearts of 20-week-old akr1b3-
null diabetic mice, AGEs of 20 and 40 kDa were detected
by anti-argpyrimidine and anti-CML antibodies (Fig. 6A
and B). Changes in AGE formation in the hearts of
wild-type and akr1b3-null mice were similar to those
observed in the plasma. Induction of diabetes was associ-
ated with greater AGE accumulation in wild-type hearts
largely because of the increase in p20 and p40 AGEs. In
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accumulation of p20 and p40 AGEs was observed. In each
case, two- to threefold increase in the abundance of these
AGEs was observed in akr1b3-null than in wild-type hearts
(Fig. 6B). However, the intensity of some of the anti-AGE
antibody–positive bands was decreased in the diabetic
aldose reductase–null mice. The reasons for this decrease
are unclear, but it is unlikely to be because of nonspeciﬁc
reactivity of the antibody, in which case the intensity
would remain the same. Because the 45 and 40 kDa
proteins show reciprocal relationship, we speculate that
the 45 and 40 kDa proteins may be the same protein and
that because of multiple AGE formation, its apparent
molecular weight shifts from 45 to 40 kDa. Further exper-
iments are, however, required to identify changes in
individual bands. Nevertheless, overall these data sup-
port the view that AKR1B3 prevents AGE formation and
that metabolism of AGE precursors by this enzyme
prevents AGE accumulation.
To examine AGE localization, sections of the diabetic
hearts were stained with the anti-argpyrimidine antibody.
Low levels of positive reactivity with the antibody were
observed in wild-type diabetic hearts. This staining was
associated strongly with blood vessels, but the cardiac
myocytes showed diffuse staining as well (Fig. 6C). Stain-
ing of both myocytes and blood vessel was two- to
threefold higher in the diabetic akr1b3-null than wild-type
hearts (Fig. 6C). These results indicate that deletion of
akr1b3 increases cardiovascular AGE accumulation in
diabetes.
To assess how AKR1B3 regulates AGE formation during
atherosclerosis, we generated akr1b3-apoE–null mice. Di-
abetes was induced by STZ, and lesion formation was
examined 12 weeks after the induction of diabetes. The
levels of blood glucose, cholesterol, and triglycerides in
akr1b3-apoE–null mice were similar to those in apoE-null
mice (supplemental Table 2). Image analysis of hematox-
ylin-eosin–stained sections of innominate arteries showed
that lesion sizes in diabetic akr1b3-apoE–null mice were
two- to threefold higher than diabetic apoE-null mice (Fig.
7A). These data support the notion that deletion of the
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apoE-null mice.
Increase in lesion formation in the akr1b3-apoE–null
mice was accompanied by an increase in AGE accumula-
tion. For quantifying AGE formation, lesions of compara-
ble sizes were stained with three different anti-AGE
antibodies. As shown in Fig. 7A, low levels of positive
staining were observed in apoE-null mice; however, the
extent of staining was three- to fourfold higher in the
akr1b3-apoE–null mice. Lesions of the akr1b3-apoE–null
mice showed increases in their reactivity to anti-argpyri-
midine, anti-CML, and anti–3-deoxyglucosone imidazolone
antibodies. Anti-argpyrimidine–positive immunostaining
was more predominant in the endothelial layer and the
highly proliferative areas of the lesions as well as smooth
muscle cells (Fig. 7B). Staining for CML was particularly
localized to atherosclerotic plaques (Fig. 7C), whereas the
staining for 3-deoxyglucosone imidazolone increased both
in smooth muscle cells and endothelial layer. Intense
staining was also observed in the adventitia (Fig. 7D).
Collectively, these data indicate that in diabetic apoE-null
mice, deletion of akr1b3 increases the formation of sev-
eral structurally different AGEs.
DISCUSSION
The major ﬁndings of this study are that aldose reductase
(AKR1B1/3/4)-catalyzed reduction is a signiﬁcant pathway
for the cardiovascular metabolism of AGE precursors and
that the reduction of AGE precursors by aldose reductase
diminishes the AGE formation and accumulation. Our
observations that aldose reductase reduces a variety of
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genetic deletion of the enzyme increases AGE accumula-
tion both in cells exposed to high glucose and in diabetic
mice provide direct evidence supporting the notion that
aldose reductase prevents AGE accumulation in vivo by
detoxifying AGE precursors. These ﬁndings provide a new
view of the role of this enzyme in the development of
secondary diabetic complications.
Formation and accumulation of AGEs has been linked
to the development of several diabetic complications
(1,25–27). The AGEs are formed by reactions of proteins
with glucose-derived carbonyls and could be generated
either inside cells or on the extracellular surface, leading
to collagen cross-linking (3). Our results, however, show
that most AGEs, at least during short-term hyperglycemia,
are generated within cells, indicating that metabolism of
AGE precursors could affect AGE formation. Intracellular
formation of AGEs suggests that their formation could be
regulated by the metabolism of AGE precursors. Indeed
the AGE precursors methylglyoxal and glyoxal have been
shown to be metabolized by glyoxalases, and overexpres-
sion of glyoxalase I prevents AGE formation in endothelial
cells cultured in high glucose (14). Nonetheless, the in vivo
role of glyoxalase I in preventing AGE formation in
diabetic animals has not been tested. Moreover, given the
limited substrate speciﬁcity of glyoxalase I, it is not clear
how AGE precursors other than methylglyoxal (e.g., de-
oxyglucosone, furfural, hydroxymethylfurfural) are metab-
olized. Therefore, we studied the AKR superfamily. Many
members of this family catalyze the reduction of keto-
aldehydes (28). We found signiﬁcant activity with AKR1A4,
AKR1B1, AKR1B3, AKR1B7, and AKR1B8. No activity was
observed with the AKR1C family. Even with AKRs, family-
wide variations in catalytic activities were observed with
different AGE precursors, indicating that these enzymes
may have a tissue-speciﬁc role such that in tissues in
which they are expressed in highest abundance, they may
be capable of metabolizing AGE precursors. Consistently
high activity was, however, observed with AKR1B1/3 (al-
dose reductase), indicating that this enzyme is likely to
play the most general and signiﬁcant role in the reduction
of AGE precursors.
Previous work shows that aldose reductase is a broad-
speciﬁcity aldehyde reductase. It catalyzes the reduction
of several endogenously generated aldehydes including
glucose, products of lipid peroxidation such as hy-
droxynonenal (28–32), as well as AGE precursors such as
methylglyoxal (16,33). Overexpression of aldose reductase
in kidney tubules decreases carbonyl content (34), and the
deletion of the aldose reductase gene in Saccharomyces
cervisiae enhances the accumulation of argpyrimidine
adducts (24). Studies from our lab show that aldose
reductase prevents ischemia injury (35) and mediates
ischemic preconditioning (36), indicating that the enzyme
may be involved in removing reactive aldehydes. The
results of the current study, however, establish for the ﬁrst
time the in vivo cardiovascular role of aldose reductase in
the metabolism of methylglyoxal and other AGE precur-
sors. Several lines of evidence indicate that aldose reduc-
tase is a signiﬁcant route of methylglyoxal metabolism.
These include data showing that 1) acetol is generated in
hearts perfused with methylglyoxal; 2) in endothelial cells
aldose reductase inhibition increases AGE formation;
and 3) reduction of methylglyoxal is increased in aldose
reductase-transgenic hearts and decreased in aldose
reductase–null hearts. A signiﬁcant, nonredundant role of
aldose reductase in the metabolism of AGE precursors is
also supported by the observation that higher AGE levels
were detected in aldose reductase–null than in wild-type
mice. In comparison with tissues of wild-type mice, aldose
reductase–null mouse heart and plasma showed higher
abundance of several AGEs that reacted with the anti-
argpyrimidine, anti-CML, and anti–3-deoxyglucosone imi-
dazolone antibodies. The difference between wild-type and
aldose reductase–null mouse tissues was evident even in
the absence of diabetes, indicating that AGEs are formed
during normal metabolism and that aldose reductase me-
tabolizes AGE precursors even under basal conditions.
A signiﬁcant role of aldose reductase in preventing AGE
accumulation, indicated by our data, is in contrast to the
current view that the polyol pathway generates AGEs
(8,37). In the polyol pathway glucose is reduced to sorbitol
by aldose reductase, and then sorbitol is converted to
fructose by sorbitol dehydrogenase. In the lens, fructose-
3-phosphate is then generated either from the phosphory-
lation of fructose by 3-phosphokinase or the reduction of
sorbitol-3-phosphate (38). Fructose-3-phosphate then
spontaneously breaks down into 3-deoxyglucosone (39),
which generates CML or imidazolone adducts (37). In
agreement with this view, it has been shown that levels of
3-deoxyglucosone are increased in erythrocytes of dia-
betic subjects and inhibition of aldose reductase decreases
the levels of CML adducts in the erythrocytes (37). None-
theless, even in the lens, fructose-3-phosphate is not
generated upon incubation with high glucose (only with
high fructose) (40). In cardiovascular tissues, it is not clear
whether the low levels of sorbitol dehydrogenase (41) are
sufﬁcient to support signiﬁcant formation of fructose from
glucose. Moreover, as shown in current study, aldose
reductase directly catalyzes the reduction of 3-
deoxyglucosone, and in contrast to changes seen in eryth-
rocytes (37), genetic deletion of aldose reductase in-
creased the abundance of CML adducts in diabetic heart
and 3-deoxyglucosone–derived imidazolone adducts in
atherosclerotic lesions of diabetic mice. This disagree-
ment may be because of differences in the tissue-speciﬁc
roles of the aldose reductase or sorbitol dehydrogenase
expression or metabolic conditions that either favor the
removal or the production of deoxyglucosone and other
AGEs by aldose reductase. Nonetheless, the observation
that lack of aldose reductase permits greater accumulation
of several structurally diverse AGEs suggests that the role
of this enzyme is more complex than previously thought
and that at least in cardiovascular tissues, aldose reduc-
tase prevents metabolites of glucose from forming AGEs.
Our results also show that atherosclerotic lesion forma-
tion in apoE-null mice was enhanced by deletion of the
aldose reductase gene. The increase in lesion formation in
ar-null mice was accompanied by greater accumulation of
AGEs. Although STZ-treated mice displayed slightly (20–
30%) higher levels of glucose, greater accumulation of
AGEs in these mice could not be directly attributed to high
glucose alone because deletion of aldose reductase in-
creased AGE accumulation in apoE-null mice without
exacerbating hyperglycemia. Furthermore, diabetic mice
accumulated AGEs that displayed positive reactivity with
anti-argpyrimidine, anti-CML, as well as anti–3-deoxyglu-
cosone imidazolone antibodies, suggesting that the lack of
aldose reductase permits greater accumulation of several
structurally diverse AGEs (Fig. 7), consistent with the
broad speciﬁcity of the enzyme observed in kinetic studies
(Table 1). Several previous studies, however, suggest that
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diabetic complications. This view is based on several
decades of work showing that inhibition of aldose reduc-
tase delays, prevents, or even reverses cataractogenesis
and neuropathy in diabetic rats (42). In addition, it has
been recently reported that general overexpression of
aldose reductase in all tissues exaggerates motor nerve
conduction velocity defect (43) and atherosclerosis in
diabetic mice (44). However, signiﬁcance of the effects of
such nonspeciﬁc increase in aldose reductase, even in
tissues where it is not basally expressed (e.g., smooth
muscle cells, liver etc), is not clear. Our results showing
that cardiac-speciﬁc overexpression of aldose reductase
increases methylglyoxal and that deletion of aldose reduc-
tase in the tissues in which it is expressed increases AGE
formation and lesion formation in mice indicates that
aldose reductase promotes the removal of AGE precursors
and increases atherosclerotic lesion formation in a tissue-
speciﬁc manner. It is also likely that the effects of aldose
reductase may also depend on the state of the disease and
the total tissue carbonyl load. Indeed, results from our
own laboratory show that inhibition of aldose reductase
prevents smooth muscle growth and diminishes restenosis
in diabetic rats (42) and also prevents high glucose–
induced inﬂammatory signaling and the release of TNF-
from vascular smooth muscle cells (45), indicating that
inhibition of the enzyme could prevent some of the harm-
ful effects of high glucose. Hence, in different metabolic
scenarios, aldose reductase may be cytoprotective by
removing toxic aldehydes or harmful because it depletes
NADPH and thereby reduces the concentration of reduc-
ing equivalents. In this regard, aldose reductase may be
similar to NF-B or reactive oxygen species, both of which
are regulated by aldose reductase and both of which could
have protective or deleterious effects depending upon the
metabolic context. Further studies are required to fully
understand the metabolic dependence of aldose reductase
action. Nevertheless, the data presented here provide
direct support to the notion that reduction of methyl-
glyoxal and related AGE precursors is a signiﬁcant meta-
bolic activity that could be ascribed to aldose reductase
and that chronic deﬁciency of this enzyme could increase
AGE accumulation and the formation of atherosclerotic
lesions.
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